Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (51-60 of 159) with videos related to

Pageof 16
Sort By:
Cancer Research|April 15, 1992
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogueC B Hendricks, E K Rowinsky, L B Grochow, et al.
Cancer Treatment Reports|May 1, 1987
Hexamethylene bisacetamide-induced cutaneous vasculitisE K Rowinsky, W P McGuire, G J Anhalt, et al.
Investigational New Drugs|January 1, 1997
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancerE K Rowinsky, W A Flood, S E Sartorius, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Camptothecin analogues: studies from the Johns Hopkins Oncology CenterW J Slichenmyer, E K Rowinsky, L B Grochow, et al.
Cancer Treatment Reports|December 1, 1987
Phase I trial of taxol in patients with advanced cancerR C Donehower, E K Rowinsky, L B Grochow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trialsJ M Gallo, P B Laub, E K Rowinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Anti-Cancer Drugs|April 1, 1997
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming unitsE Raymond, A Hanauske, S Faivre, et al.
Investigational New Drugs|November 1, 1989
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I studyE K Rowinsky, L B Grochow, A Hantel, et al.
Leukemia|June 1, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrationsE K Rowinsky, B A Conley, R J Jones, et al.
Pageof 16

Showing results (51-60 of 159) with videos related to

Sort By:
Pageof 16
Cancer Research|April 15, 1992
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogueC B Hendricks, E K Rowinsky, L B Grochow, et al.
Cancer Treatment Reports|May 1, 1987
Hexamethylene bisacetamide-induced cutaneous vasculitisE K Rowinsky, W P McGuire, G J Anhalt, et al.
Investigational New Drugs|January 1, 1997
Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancerE K Rowinsky, W A Flood, S E Sartorius, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Camptothecin analogues: studies from the Johns Hopkins Oncology CenterW J Slichenmyer, E K Rowinsky, L B Grochow, et al.
Cancer Treatment Reports|December 1, 1987
Phase I trial of taxol in patients with advanced cancerR C Donehower, E K Rowinsky, L B Grochow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trialsJ M Gallo, P B Laub, E K Rowinsky, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic studyE K Rowinsky, S D Baker, K Burks, et al.
Anti-Cancer Drugs|April 1, 1997
Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming unitsE Raymond, A Hanauske, S Faivre, et al.
Investigational New Drugs|November 1, 1989
Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I studyE K Rowinsky, L B Grochow, A Hantel, et al.
Leukemia|June 1, 1992
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrationsE K Rowinsky, B A Conley, R J Jones, et al.
Pageof 16